Supports optimum prostate health*
Supports management of healthy urinary function*
Promotes healthy male hormone balance*
Serving Size: 1 capsule Fructus Serenoae Repentis (Jù Z?ng L?) 10mg Gummi Olibanum (R? Xi?ng) (contains: standardized 5-Loxin (30% AKBA)) 30mg Radix Urticaceae (Qián Má) 80mg Rhizoma Dioscoreae Hypoglaucae (Bì Xiè) 80mg Fructus Alpiniae Oxyphyllae (Yì Zhì Rén) 50mg Radix Linderae Strychnifoliae (W? Yào) 50mg Rhizoma Acori Graminei (Shí Ch?ng Pú) 50mg Fructus Ligustri Lucidi (N? Zh?n Z?) 20mg Boron (as boron citrate/aspartate/glycinate complex) 0.7mg Glycine Max (contains: standardized Beta-Sitosterol) 39.3mg.Suggested Use: 3-4 caps daily.
Prostate Protect is a complex herbal formula with standardized 5-Loxin (30% AKBA) Boron and standardized Beta-Sitosterol together with herbs traditionally used to support a healthy male urogenital system. BPH is the most common prostate disease. BPH usually starts after the age of 40 years and is more common in older men; it affects nearly all men at some time in their lives.* Prostate Protect contains Boswellia (Frankincense). Published studies show that normal aging and poor diet cause levels of a dangerous enzyme (5-lipoxygenase) to increase, which can affect prostate cells. (1) Extracts from the boswellia plant, has been shown to suppress 5-lipoxygenase (5-LOX) and other proinflammatory factors. (2,3,4) Prostate Protect has been designed to support prostate health and support management of associated signs of BPH.*
1. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 2004 Apr;24(4):821-7.
2. Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997 Apr;281(1):460-3.
3. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995 Jun;47(6):1212-6.
4. Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory disease. Wien Med Wochenschr. 2002;152(15-16):373-8.